(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
18 September 2008 (18.09.2008)

PCT

(10) International Publication Number
WO 2008/112934 A1

(51) International Patent Classification:
A61K 9/00 (2006.01) *A61P 35/00* (2006.01)
A61K 31/404 (2006.01)

(21) International Application Number:
PCT/US2008/056912

(22) International Filing Date: 13 March 2008 (13.03.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/894,610 13 March 2007 (13.03.2007) US

(71) Applicant *(for all designated States except US)*: **SPECTRUM PHARMACEUTICALS, INC.** [US/US]; 157 Technology Drive, Irvine, CA 92618 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **LENAZ, Luigi** [US/US]; 11 Planetree Court, Newton, PA 18940 (US). **CHAWLA, Shanta** [US/US]; 34 Modesto, Irvine, CA 92602 (US). **BEER, Mario** [US/US]; 311 Acebo Lane Apt. D, San Clemente, CA 92672 (US).

(74) Agents: **CULLMAN, Louis, C.** et al.; Kirkpatrick & Lockhart Preston Gates Ellis LLP, 1900 Main Street, Sixth Floor, Irvine, CA 92614-7319 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

WO 2008/112934 A1

(54) Title: INTRAVESICAL APAZIQUONE ADMINISTRATION FOLLOWING TRANSURETHRAL RESECTION FOR TREATING CANCER

(57) Abstract: Bladder cancer treatments include the intravesical administration of apaziquone immediately (e.g. within about 6 hours) following transurethral resection.